Hydroxychloroquine & Lupus: An Old Malaria Drug's Second Life
One of the cornerstone drugs for lupus started life as an antimalarial — and it's a remarkably gentle, effective mainstay of treatment. Its story ties the antimicrobial chapter to autoimmune disease, and carries one specific, famous side effect that every patient on it is monitored for.
Systemic lupus erythematosus — lupus for short — is an autoimmune disease in which the immune system can attack almost any part of the body: the skin, the joints, the kidneys, the blood, the brain. It's variable and unpredictable, ranging from mild skin and joint symptoms to severe, organ-threatening disease. Its treatment spans much of what you've already learned — steroids for flares, and immunosuppressants like mycophenolate or cyclophosphamide for serious organ involvement. But there's one drug that sits at the foundation of nearly all lupus treatment, and it has a surprising origin story: hydroxychloroquine, a drug that began as an antimalarial.
The antimalarial that treats autoimmune disease
A gentle, foundational drug for almost every lupus patient. Hydroxychloroquine (and its relative chloroquine) will be familiar from the antimalarial section — they were developed to treat and prevent malaria. It turned out, somewhat by chance, that these drugs also have a useful immune-modulating effect, gently calming the overactive immune system in autoimmune diseases. In lupus, hydroxychloroquine has become a foundational, long-term treatment — most patients with lupus are kept on it, because it reduces flares, helps the skin and joint symptoms, and has even been shown to improve long-term outcomes and survival. It's also used in rheumatoid arthritis as one of the milder DMARDs. Its great appeal is that, compared with steroids and the stronger immunosuppressants, it's relatively gentle and well-tolerated, without the heavy immune-suppression and infection risk of the drugs in the last article. So it forms a safe backbone on which other treatments are added as needed. A drug born to fight a parasite, quietly repurposed to calm the immune system — another example of a medicine defined by its effects, not by the disease it was first made for.
The one side effect to watch: the eyes
Although hydroxychloroquine is generally well-tolerated, it carries one specific, well-known side effect that every patient on long-term treatment is monitored for: eye damage. With prolonged use, it can (rarely) deposit in and damage the retina — the light-sensing layer at the back of the eye — potentially harming vision, an effect called retinopathy. This is uncommon and dose-related, and it's the reason patients on long-term hydroxychloroquine have regular eye checks (retinal screening) to catch any early changes before vision is affected. It's the one thing to remember about this otherwise gentle drug. Stepping back, hydroxychloroquine rounds out the picture of how autoimmune diseases like lupus are treated: a foundation of this gentle immune-modulator for nearly everyone, steroids to control flares, and the stronger immunosuppressants (or, increasingly, biologics) reserved for severe, organ-threatening disease. The through-line of this whole autoimmune section is a single balancing act you now know well — calming an immune system that has turned on the body, using the gentlest effective drug and escalating only as far as the disease demands, always weighing control of the disease against the price of a weakened defence.
- Hydroxychloroquine is an antimalarial that also gently modulates the immune system.
- It's a foundational long-term treatment for lupus (reduces flares, helps skin/joints, improves outcomes).
- Relatively gentle and well-tolerated — without the heavy immune suppression of the stronger drugs.
- The key side effect: retinal damage (retinopathy) with long-term use → regular eye screening.
- Lupus overall: hydroxychloroquine foundation + steroids for flares + stronger immunosuppressants for severe disease.
Hydroxychloroquine is a lovely closing example of a theme that has recurred throughout this book: drugs are defined by their mechanism, not by the disease they were born to treat. It was created to kill the malaria parasite, but it happens to have a gentle immune-calming effect — and that second, almost accidental property made it one of the most valuable drugs in lupus, a completely unrelated disease. The same story has appeared again and again: aspirin the painkiller becoming a heart drug, sildenafil for the lungs, metronidazole for both bacteria and parasites, methotrexate as both chemotherapy and antirheumatic. Once you stop tying a drug to a single disease and start seeing it as a mechanism looking for problems it can solve, medicine becomes far more connected — and a drug turning up in a surprising place stops being surprising at all.
- Not arranging regular eye screening for a patient on long-term hydroxychloroquine (retinopathy).
- Overlooking hydroxychloroquine's value in lupus because it seems 'just an antimalarial'.
- Reaching for strong immunosuppressants in mild lupus before using the gentle foundation drug.
- Confusing hydroxychloroquine's gentleness with the heavy immunosuppressants' infection risk.
What is the key side effect to monitor with long-term hydroxychloroquine?
- Hydroxychloroquine is an antimalarial that gently modulates the immune system.
- It's the foundational long-term drug for lupus (reduces flares, improves outcomes) and a mild DMARD in RA.
- Relatively gentle — without the heavy immunosuppression of the stronger drugs.
- Key side effect: retinal damage with long-term use → regular eye screening.
- Katzung BG. Basic & Clinical Pharmacology — DMARDs (antimalarials in rheumatic disease).
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Antimalarials & immunomodulation.
- ACR / EULAR — Hydroxychloroquine in SLE; retinopathy screening guidelines.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Hydroxychloroquine.
